Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe

Roche (RHHBY) announced that the European Commission has approved its lymphoma drug, Columvi (glofitamab), for second-line treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (“DLBCL”).The regulatory body in Europe has now approved Columvi in combination with gemcitabine and oxaliplatin (GemOx) for treating R/R DLBCL in adult patients who are not otherwise specified or eligible for autologous stem cell transplant.The approval in the European Union was expected as the Committee for Medici ...